Smith Karen Lisa, Isaacs Claudine
Washington Cancer Institute, Washington Hospital Center, Washington DC 20010, USA.
Breast Dis. 2006;27:51-67. doi: 10.3233/bd-2007-27104.
This chapter reviews the management of women at increased risk for hereditary breast cancer. Screening strategies, emphasizing new data regarding magnetic resonance imaging (MRI), are discussed. It is recommended that women at risk for hereditary breast cancer consider annual MRI in addition to mammography and clinical breast examinations. Next, currently available data regarding chemoprevention and surgical prophylaxis for women at high risk for hereditary breast cancer are reviewed. Chemoprevention with tamoxifen reduces the risk of breast cancer by approximately 50% in a heterogeneous population of high risk women; however, the benefit in women at risk for hereditary breast cancer is less clear. In contrast, surgical prophylaxis with bilateral mastectomy reduces the risk of breast cancer by at least 90% and bilateral oophorectomy reduces the risk of breast cancer by approximately 50% among high risk women. Next, ways in which BRCA mutation-associated breast cancers differ from sporadic breast cancers are reviewed. Unique management issues pertaining to women with hereditary breast cancer are then discussed with an emphasis on surgical decision making and peri-diagnostic genetic counseling and testing. Finally, the management of women at risk for hereditary breast cancer in whom deleterious mutations are not identified is reviewed.
本章回顾了遗传性乳腺癌高危女性的管理。讨论了筛查策略,重点是关于磁共振成像(MRI)的新数据。建议遗传性乳腺癌高危女性除了进行乳房X线摄影和临床乳房检查外,还应考虑每年进行MRI检查。接下来,回顾了目前关于遗传性乳腺癌高危女性化学预防和手术预防的可用数据。在高危女性的异质性群体中,他莫昔芬化学预防可使乳腺癌风险降低约50%;然而,对遗传性乳腺癌高危女性的益处尚不清楚。相比之下,双侧乳房切除术手术预防可使高危女性的乳腺癌风险降低至少90%,双侧卵巢切除术可使乳腺癌风险降低约50%。接下来,回顾了BRCA突变相关乳腺癌与散发性乳腺癌的不同之处。然后讨论了遗传性乳腺癌女性的独特管理问题,重点是手术决策以及诊断前后的遗传咨询和检测。最后,回顾了未发现有害突变的遗传性乳腺癌高危女性的管理。